Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

Phase 3

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide
Drug: Azathioprine
Drug: Corticosteroid
Drug: Placebo to Azathioprine
Drug: Placebo to Mycophenolate mofetil

First Posted Date: 2006-09-18

Last Posted Date: 2011-12-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 370

Registration Number: NCT00377637

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2006-09-15

Last Posted Date: 2017-11-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 68

Registration Number: NCT00376961

Locations: 🇺🇸
Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States
🇺🇸
Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States
🇺🇸
Providence Cancer Center, Anchorage, Alaska, United States

and more 143 locations

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Phase 1

Terminated

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Secondary Myelofibrosis

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: Treg cell infusion
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2006-09-15

Last Posted Date: 2017-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 3

Registration Number: NCT00376519

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total body irradiation
Other: Natural killer cell infusion
Biological: Interleukin-2

First Posted Date: 2006-09-15

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 6

Registration Number: NCT00376805

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
X-linked Lymphoproliferative Disease (XLP)
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Familial Hemophagocytic Lymphohistiocytosis (FLH)
Viral-associated Hemophagocytic Syndrome (VAHS)
Hemophagocytic Lymphohistiocytosis (HLH)
Acute Lymphoblastic Leukemia
Non Hodgkins Lymphoma

Interventions: Drug: Ara-C
Drug: Cyclophosphamide
Biological: Campath-1H
Radiation: Total Body Irradiation
Procedure: Stem Cell Infusion

First Posted Date: 2006-08-24

Last Posted Date: 2020-01-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 46

Registration Number: NCT00368355

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hosptial, Houston, Texas, United States

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Capecitabine
Drug: Docetaxel

First Posted Date: 2006-08-17

Last Posted Date: 2021-04-13

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 45

Registration Number: NCT00365417

Locations: 🇺🇸
NSABP Foundation, Inc., Pittsburgh, Pennsylvania, United States

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

First Posted Date: 2006-08-17

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00365755

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Phase 1

Completed

Conditions: Breast Cancer
Lymphoma
Leukemia
Myelodysplastic Syndromes
Kidney Cancer
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-08-17

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 148

Registration Number: NCT00365287

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Phase 2

Terminated

Conditions: Anaplastic Large Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Drug: SGN-30

First Posted Date: 2006-08-17

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT00365274

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

Phase 1

Conditions: Lymphoma

First Posted Date: 2006-08-15

Last Posted Date: 2013-09-20

Lead Sponsor: Toronto Sunnybrook Regional Cancer Centre

Target Recruit Count: 84

Registration Number: NCT00363090

Locations: 🇨🇦
St. Paul's Hospital at Providence Health Care - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
Odette Cancer Centre at Sunnybrook, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy